Patent-protected drugs imported from abroad may now face a 100 percent tariff upon entering the United States, according to the White House. However, exporting companies can avoid this tariff by entering into agreements with the U.S. government. After signaling such measures for a long time, U.S. President Donald Trump has finally announced the policy, which aims to increase domestic production of critical medicines and reduce national security risks. The move, however, is largely symbolic at present, as it does not apply to generic drugs, which are the most widely used in the United States. Many major pharmaceutical companies have already secured tariff exemptions through agreements, and more companies are expected to follow, with Sean Sullivan noting that the policy is primarily a negotiation tactic. Under the terms, companies that commit to begin production in the U.S. by January 2029 will face a reduced tariff of 20 percent, and if they agree to government-set pricing for their drugs, the tariff could be eliminated entirely. Some companies have already agreed to sell certain drugs at prices equivalent to foreign markets under programs such as Medicaid. Additionally, the United States will maintain previous lower-tariff agreements with key partners including Europe, Switzerland, the United Kingdom, South Korea, and Japan. Under a December agreement with the United Kingdom, medicines sent from the UK to the U.S. will remain tariff-free, while the UK will pay higher prices through its NHS system, granting British-made drugs three years of tariff-free access in return. The UK government has described this partnership as a win for patients, business, and the economy, and sees it as an incentive to accelerate the introduction of new treatments. Senior U.S. officials have said that major companies will have 120 days and small to medium-sized firms 180 days to reach agreements, noting that companies have already been given sufficient warning and implementation is underway. However, Richard Frank of the Brookings Institution points out that the actual impact remains uncertain, as it is unclear how many drugs will qualify for exemptions and how many companies will sign agreements. While large companies may benefit, smaller firms could face increased costs due to the tariffs. The Trump administration seeks to boost domestic production, which generally raises costs, although pricing agreements can help mitigate expenses; so far, the announced agreements are limited in scope. The White House claims that the threat of tariffs has already prompted companies to pledge roughly $400 billion in U.S. investments. After President Trump’s term ends in January 2029, these reduced-tariff opportunities will no longer be available. Meanwhile, the administration is also revising tariff conditions on steel, aluminum, and copper, exempting products that contain negligible amounts of these metals from tariffs.
US imposes 100 percent tariff on imported medicines
